Chad Tang, MD, The University of Texas MD Anderson Cancer Center, discusses the design of the randomized, phase 2, basket EXTEND trial.
Chad Tang, MD, The University of Texas MD Anderson Cancer Center, discusses the design of the randomized, phase 2, basket EXTEND trial (NCT03599765).
In EXTEND, investigators examined whether or not the addition of metastasis directed therapy improved progression-free survival in men with oligometastatic solid tumors, including prostate cancer.
Patients were randomly assigned to continue hormone therapy with or without metastasis directed therapy after at least 2 months of hormone therapy alone. Hormone therapy was then stopped 6 months after enrollment and patients did not resume until progression.
Transcription:
0:08 | EXTEND is a basket study, which means we were looking at multiple histologies where each basket is powered by itself to look at a question. In this intermittent hormone therapy basket, patients with oligometastatic prostate cancer chosen to be on intermittent hormone therapy were randomized to radiation therapy versus not. Then the hormone therapy was stopped 6 months later, so you get a minimum of 8 months, because you needed 2-4 months before.
0:46 | This kind of mirrors an intermittent hormone regime. Then, patients were monitored and when their PSA [prostate specific antigen] rises, we call it progression when they meet certain thresholds, you put the patient's back on hormone therapy. The primary end point was progression-free survival, which could be from PSA or from your graphical assessment. Secondarily, we were trying to see how long patients could be off the hormones and have normal testosterone because all men who were on hormone therapy hate it. They want their testosterone back as it is a big quality of life impact for them.
FPI-2265 Dosing Commences in Phase 2 AlphaBreak Trial for mCRPC
May 10th 2024The first patient has been dosed in the phase 2 AlphaBreak trial with FPI-2265 for the treatment of metastatic castration-resistant prostate cancer, marking a significant milestone in advanced cancer treatment.
Read More
First Real-World Data on Second-Generation AR Inhibitor Use in nmCRPC
September 18th 2023A review of real-world data from the DEAR study of darolutamide, enzalutamide and apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer is given by Alicia Morgans, MD, MPH.
Listen